Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYanan YueXBXiangji BianXSXiao‐Yu Song

Discussion

Loading...

Member takes

Overview

Chimeric antigen receptor T cells improved NK cell resistance in a clinical evaluation of allogeneic immunotherapy, suggesting potential for off-the-shelf applications.

Key Points

  • UCAR-T cells engineered for immune evasion significantly enhanced NK cell resistance, improving survival rates.
  • Evaluation of UCAR-T candidates revealed their preclinical efficacy against tumors during ongoing clinical trials.
  • Engineering approaches included TCR knockout and hypo-immunity strategies, aimed at reducing allogeneic rejection risks.
  • Promising results support the potential for off-the-shelf CAR T cell therapy in treating refractory autoimmune diseases.

Cite This Study

Yue et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d462https://doi.org/10.1182/blood-2025-1045
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recent advances in universal chimeric antigen receptor T cell therapy2025 · 30 citations
  2. 2A Novel Early Memory-Enriched Allogeneic NKG2D CAR-T Cell Therapy Based on CRISPR/Cas9 Technology for Solid Tumors2025
  3. 3CAR-based cell therapy for autoimmune diseases2025 · 6 citations
  4. 4CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia.2025 · 3 citations
  5. 5Allogeneic NKG2D CAR-T Cell Therapy: A Promising Approach for Treating Solid Tumors2025